Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung Cancers.

[1]  N. Seetharamu,et al.  The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab. , 2022, Cancer medicine journal.

[2]  Raymond Y Huang,et al.  Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis. , 2021, AJR. American journal of roentgenology.

[3]  Neha M Jain,et al.  Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis. , 2021 .

[4]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[5]  A. Dekker,et al.  Repeatability and reproducibility study of radiomic features on a phantom and human cohort , 2021, Scientific Reports.

[6]  Matthias Guckenberger,et al.  Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients. , 2020, Medical physics.

[7]  I. Locke,et al.  Systemic treatment of brain metastases in non-small cell lung cancer. , 2020, European journal of cancer.

[8]  M. Perelman,et al.  Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling , 2020, Translational lung cancer research.

[9]  J. Palva,et al.  Influence of multiple hypothesis testing on reproducibility in neuroimaging research: A simulation study and Python-based software , 2020, Journal of Neuroscience Methods.

[10]  Mitsuhiro Nakamura,et al.  Comparison of radiomic features in diagnostic CT images with and without contrast enhancement in the delayed phase for NSCLC patients. , 2020, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[11]  Sharyn I. Katz,et al.  Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Cuntai Guan,et al.  A Survey on Explainable Artificial Intelligence (XAI): Toward Medical XAI , 2019, IEEE Transactions on Neural Networks and Learning Systems.

[13]  Jonathan H. Chung,et al.  ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer. , 2019, Journal of the American College of Radiology : JACR.

[14]  Derek E. Smith,et al.  The Incidence of Brain Metastases in Stage IV ROS1‐Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Florian Lemmerich,et al.  pysubgroup: Easy-to-Use Subgroup Discovery in Python , 2018, ECML/PKDD.

[17]  H. Groen,et al.  Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Govindan,et al.  Non–small‐cell Lung Cancer With Brain Metastasis at Presentation , 2018, Clinical lung cancer.

[19]  R. Valicenti,et al.  Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer , 2018, Technology in cancer research & treatment.

[20]  Laurence Court,et al.  Effect of tube current on computed tomography radiomic features , 2018, Scientific Reports.

[21]  Tie-Yan Liu,et al.  LightGBM: A Highly Efficient Gradient Boosting Decision Tree , 2017, NIPS.

[22]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[23]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[24]  K. Rabe,et al.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.

[25]  A. Iafrate,et al.  Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. , 2017, JCO precision oncology.

[26]  Xiaohua Liang,et al.  High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases , 2017, Journal of Neuro-Oncology.

[27]  Russell T. Shinohara,et al.  Harmonization of cortical thickness measurements across scanners and sites , 2017, NeuroImage.

[28]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[29]  Stuart A. Taylor,et al.  Imaging biomarker roadmap for cancer studies , 2016, Nature Reviews Clinical Oncology.

[30]  F. Hirsch,et al.  New and emerging targeted treatments in advanced non-small-cell lung cancer , 2016, The Lancet.

[31]  W. Weichert,et al.  Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom , 2016, Der Pathologe.

[32]  A. Nichol,et al.  EGFR mutation status on brain metastases from non-small cell lung cancer. , 2016, Lung cancer.

[33]  Sumyea Helal.  Subgroup Discovery Algorithms: A Survey and Empirical Evaluation , 2016, Journal of Computer Science and Technology.

[34]  Hojoong Kim,et al.  Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  M. Watson,et al.  Brain Metastases at Presentation in Patients With Non–Small Cell Lung Cancer , 2015, American journal of clinical oncology.

[36]  Nicholas G Zaorsky,et al.  Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[37]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  M. Shingyoji,et al.  Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations , 2015, International Journal of Clinical Oncology.

[39]  Moon Soo Kim,et al.  A nomogram to predict brain metastasis as the first relapse in curatively resected non-small cell lung cancer patients. , 2015, Lung cancer.

[40]  D. Costa,et al.  Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. , 2015, Lung cancer.

[41]  J. Soria,et al.  Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study , 2015, Clinical Cancer Research.

[42]  Dong-Yeop Shin,et al.  EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  D. Christiani,et al.  Women and lung cancer: what is new? , 2013, Seminars in thoracic and cardiovascular surgery.

[44]  K. Kelly,et al.  Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. , 2014, Lung cancer.

[45]  L. Luo,et al.  Differentiation of Central Lung Cancer from Atelectasis: Comparison of Diffusion-Weighted MRI with PET/CT , 2013, PloS one.

[46]  H. Choy,et al.  Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Hainaut,et al.  KRAS mutation status in primary nonsmall cell lung cancer and matched metastases , 2010, Cancer.

[48]  Gavin C. Cawley,et al.  On Over-fitting in Model Selection and Subsequent Selection Bias in Performance Evaluation , 2010, J. Mach. Learn. Res..

[49]  J. Subramanian,et al.  Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  G. Scagliotti,et al.  Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  Si Yu Wang,et al.  Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. , 2009, Lung cancer.

[52]  J. Li,et al.  Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study , 2009, European Radiology.

[53]  M. Loda,et al.  Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma , 2008, Cancer.

[54]  A. Jena,et al.  Magnetic Resonance (MR) Patterns of Brain Metastasis in Lung Cancer Patients: Correlation of Imaging Findings with Symptom , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  L. Gaspar,et al.  Prophylactic cranial irradiation for patients with lung cancer. , 2007, Clinical lung cancer.

[56]  Charles A Powell,et al.  Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. , 2007, Radiology.

[57]  Achim Zeileis,et al.  Bias in random forest variable importance measures: Illustrations, sources and a solution , 2007, BMC Bioinformatics.

[58]  E. Quoix,et al.  [Lung cancer in women]. , 2005, Revue des maladies respiratoires.

[59]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[60]  M. Cho,et al.  Screening of Brain Metastasis with Limited Magnetic Resonance Imaging (MRI): Clinical Implications of Using Limited Brain MRI During Initial Staging for Non-small Cell Lung Cancer Patients , 2005, Journal of Korean medical science.

[61]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  B. Yawn,et al.  Temporal and gender-related trends in brain metastases from lung and breast cancer. , 2003, Minnesota medicine.

[63]  A. Carretta,et al.  Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment , 2002, Cancer.

[64]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[65]  K. Mori,et al.  Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. , 1999, Chest.

[66]  L. C. Swenson,et al.  MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. , 1994, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[67]  L. Jacobs,et al.  'Silent' brain metastasis from lung carcinoma determined by computerized tomography. , 1977, Archives of neurology.

[68]  F. Burel-Vandenbos,et al.  EGFR mutation status in brain metastases of non-small cell lung carcinoma , 2012, Journal of Neuro-Oncology.

[69]  Martin Atzmüller,et al.  Subgroup discovery , 2005, Künstliche Intell..

[70]  L. Breiman.  Random Forests , 2001, Machine Learning.

[71]  C. Bucana,et al.  The seed and soil hypothesis: vascularisation and brain metastases. , 2002, The Lancet. Oncology.

[72]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .